RPG Deepens Pharma Manufacturing Push with Second API Acquisition
What Happened
RPG Life Sciences’ wholly owned subsidiary RPG Active Pharma has agreed to acquire the API (Active Pharmaceutical Ingredients) and intermediates business of Raghava Life Sciences for up to ₹135 crore. The deal includes a Hyderabad-based manufacturing facility, 22 commercialised APIs and 7 development-stage products across therapeutic areas such as diabetes, cardiovascular and CNS disorders.
Key Takeaways
The acquisition strengthens RPG’s API manufacturing footprint and follows its recent purchase of Actis Generics. It is part of the company’s strategy to build a larger, integrated API platform and capture a greater share of the growing global pharmaceutical ingredients market.